AMGEN INC
Close on Oct 19, 2026
- Market cap
- $231.17B
- P/E (TTM)
- 26.4
- Dividend yield
- 2.27%
Earnings
Next report expected Nov 3, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | During market hours | $10.10B | $4.37 | $6.29 |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | During market hours | $8.60B | $3.34 | $5.15 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 3, 2026 | During market hours | $9.90B | $2.45 | $5.29 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | During market hours | $9.60B | $5.93 | $5.64 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | During market hours | $9.20B | $2.65 | $6.02 |
| Q1 FY2025 Ended Mar 31, 2025 | May 1, 2025 | During market hours | $8.10B | $3.20 | $4.90 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 4, 2025 | During market hours | $9.10B | $1.16 | $5.31 |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 30, 2024 | During market hours | $8.50B | $5.22 | $5.58 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 6, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Aug 4, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Capital expenditures | full year 2026 | $2.60B | Maintained |
| EPSnon-GAAP | full year 2026 | $22.30 to $23.50 | Raised |
| EPSGAAP | full year 2026 | $15.80 to $17.08 | Narrowed |
| tax ratenon-GAAP | full year 2026 | 15% to 16.5% | Maintained |
| tax rateGAAP | full year 2026 | 14.5% to 16% | Maintained |
| Share repurchases | full year 2026 | $3.00B | Maintained |
| Total revenues | full year 2026 | $38.20B to $39.40B | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Amgen filed with the SEC
AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
AMGEN COMPLETES ACQUISITION OF HORIZON
Acquisition or disposition completed · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
AMGEN REPORTS SECOND QUARTER FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
AMGEN RESPONDS TO FTC ACTION RE:
Regulation FD disclosure · EX-99.1 to Form 8-K
AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
Material agreement · Results of operations · Other events · EX-99.1 to Form 8-K
Recast of 2021 Non-GAAP Financial Information As Reported to Reflect Updated Non-GAAP Policy
Material agreement · Results of operations · Other events · EX-99.2 to Form 8-K
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE
Regulation FD disclosure · EX-99.1 to Form 8-K
AMGEN REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
Recast of 2021 Non-GAAP Financial Information As Reported to Reflect Updated Non-GAAP Policy
Results of operations · EX-99.2 to Form 8-K
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
Regulation FD disclosure · EX-99.1 to Form 8-K
AMGEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
Recast of 2021 Non-GAAP Financial Information As Reported to Reflect Updated Non-GAAP Policy
Results of operations · EX-99.2 to Form 8-K
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
AMGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
Recast of 2021 Non-GAAP Financial Information As Reported to Reflect Updated Non-GAAP Policy
Results of operations · EX-99.2 to Form 8-K
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
AMGEN REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K